6-K

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM6-K

REPORTOF FOREIGN PRIVATE ISSUER

PURSUANTTO RULE 13a-16 OR 15d-163

UNDERTHE SECURITIES EXCHANGE ACT OF 1934

Forthe month of November 2024

AlterityTherapeutics Limited

(Name of Registrant)

Level 14, 350 Collins Street,Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicateby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

ThisForm 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980and 333-228671) and ourRegistration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417and 333-250076)

ALTERITYTHERAPEUTICS LIMITED

(adevelopment stage enterprise)

The following exhibits are submitted:

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 19, 2024

2

Exhibit 99.1

Change of Company Secretary

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA– 19 November 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), has announced the appointment of Abby Macnish Niven as Alterity’s Company Secretary following her appointment as Chief Financial Officer of Alterity. Ms Macnish Niven assumes the role of Company Secretary from Mr Phillip Hains effective on 18 November 2024.

The Board and Management of Alterity thank Phillip for his valuable contributions over the past several years and appreciate the foundation he helped establish.

Ms Macnish Niven was appointed as CFO on 30 September 2024 and has extensive experience in private wealth management with groups including ANZ, UBS and Ord Minett. Ms Macnish Niven consults to a range of listed and unlisted companies in governance, finance and corporate structure. Ms Macnish Niven holds Bachelor of Commerce and Bachelor of Science degrees from the University of Western Australia and is a Chartered Finance Analyst.

For the purposes of ASX Listing Rule 12.6, Ms Macnish Niven will be the person responsible for communications between the Company and ASX.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com.

Authorisation & Additional information

This announcement was authorised by David Stamler, CEO of Alterity Therapeutics Limited.

Investor and Media Contacts:

Australia

Ana Luiza Harrop

we-aualteritytherapeutics@we-worldwide.com

+61 452 510 255

U.S.

Remy Bernarda

remy.bernarda@iradvisory.com

+1 (415) 203-6386

Forward Looking Statements

This press release contains "forward-lookingstatements" within the meaning of section 27A of the identify such forward-looking statements by use of such words as "expects,""intends," "hopes," "anticipates," "believes," "could," "may," "evidences"and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could cause actual resultsto differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors”in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including,but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation,progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any otherstatements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risksand uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketingof the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional futuresources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, butnot limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company'sintellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertaintyof the Company freedom to operate.

Any forward-looking statement made by us inthis press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertakeno obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether asa result of new information, future developments or otherwise.